Écrit par DIA Mardi, 15 Janvier 2013 13:14 -



HORSHAM, PA, USA — January 14, 2013 — Amsterdam will play host to more than **3,000** professionals

involved in the

development of medicines

from more than 50 countries at the DIA's 25

Annual

EuroMeeting

from March 4-6.

As a neutral global forum <u>EuroMeeting 2013</u> will feature more than 110 sessions, 200 exhibitors and speakers from the European Medicines Agency, the European Commission, the Food and Drug Administration and other regulatory agencies from around the world. The event will bring together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centers, health ministries and delegates from patient organizations to share knowledge focusing on better public health protection, greater transparency of processes and the rational use of medicinal products.

Beatriz Vicén Banzo, Head of Public Affairs and Technical Department in Bayer Spain, said: "The proposed areas for discussion for EuroMeeting 2013 are classified into general disciplines including pharmacovigilance and regulatory affairs for medicinal products and medical devices, research and development, and clinical trials. The scope of the presentations will cover the experience gathered after the implementation of the new pharmacovigilance legislative framework."

The Pharmacovigilance Directive, which has applied in the EU since July 2012, sets out new legislation and guidance for the continuous monitoring of a medicines' safety and actions to reduce risks and increase the benefits of medicines.

Peter Bachmann, Chair of The Co-ordination Group for Mutual Recognition and Decentralised

New legislation on monitoring medicines' safety the hot topic at DIA's EuroMeeting 2013

Écrit par DIA Mardi, 15 Janvier 2013 13:14 -

Procedures(CMDh), added: "Knowing what still needs to be done – or improved – and most importantly: 'are we getting what was initially expected from the Pharmacovigilance Directive?'. These are some of the key areas that the professionals attending the meeting will be able to learn about and debate. Other important topics include the Falsified Medicines and Information to Patients directives and considerations over an ageing population and the potential impact on hospitalizations."

To register to attend, or for more information, visit the <u>EuroMeeting 2013</u> website at <u>www.diah</u> <u>ome.org/EM2013</u>

. Register by January 17 and save with an Early Bird discount.

ABOUT DIA

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China. www.diahome.org